Clinical Trial Search

Primary: Number of Participants Reporting Local Reactogenicity Events Signs and Symptoms: Erythema and/or Induration — 11; 10; 12; 9 Participants

Primary: Proportion or Participants Experiencing a Dose-limiting Toxicity — 0.0 percentage of participants

Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 1 Participants

Primary: Safety and Tolerability of AV-1959R Compared to Placebo — 5; 1; 6; 2 Participants

Primary: Part 1 SAD: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 3; 3; 6; 4 Participants

Primary: Rate of Periprosthetic Infection (PJI) After Elective Total Joint Arthroplasty. — 7; 0; 3; 2 Participants

Primary: Area Under the Concentration Versus Time Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of MK-8527 in Plasma — 769; 1160; 1430 nM·hr

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade (RSV-seropositive Participants) — 10; 9; 4; 0 Participants

Primary: Number of Participants With Treatment-emergent Adverse Events as Classified by MedDRA — 2; 2; 1; 2 Participants

Primary: Maximum Plasma Concentration (Cmax) of Brexpiprazole in Plasma After Administration in a Fed State Versus Administration in a Fasting State — 221.9; 365.2 ng/mL

Primary: Change in Craving Score — -0.7; -0.3 score — p=< 0.001

Primary: Changes From Baseline (Cavg) for Serum Testosterone Levels in Females After Secondary Exposure to Nestorone + Testosterone Combination Gel — 22.84; 27.12; 29.12; 62.06…

Primary: Rate of Dose Limiting Toxicity — 0 participants

Primary: Number of Adverse Events — 3; 0; 2; 2 event

Primary: Number of Unexpected Adverse Events — 41 adverse events